Cambridge, USA-based Parabilis Medicines (formerly FogPharma), a clinical-stage biopharmaceutical company committed to ...

Danish drug developer Ascendis Pharma yesterday announced top-line results from Week 52 of COACH, the first Phase II clinical ...

US commercial stage precision-care company Octave Bioscience has announced the appointment of Kirk Stockwood as senior vice ...

US pharma major Pfizer (NYSE: PFE) has struck a non-exclusive research collaboration with Gordian Bio to identify new ...

A clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, with research and development operations ...

TECregen, a Swiss biotech advancing thymus regeneration, has announced the successful completion of a 10 million Swiss francs ...

European private equity company Andera Partners today announced that it is co-leading a $159.8 million Series A round of ...

UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...

The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, ...

Swiss specialty drugmaker Santhera Pharmaceuticals announces it has signed an exclusive licensing agreement with Nxera Pharma ...

Swiss biotech TECregen has raised 10 million Swiss francs ($12.6 million) in seed financing to advance its thymus ...

UK-based clinical-stage ophthalmic gene therapy biotech Beacon Therapeutics today announced that it has raised over $75 ...